Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Candesartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | AGTR2 | P50052 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Candesartan SCHEMBL29687505 | 1.00 | ABCB11 (1.00) | ABCB11EGFRERBB2CYP3A4ADORA3 | |
| SCHEMBL29726879 | 0.94 | AGTR1 (0.88) | ABCB11EGFRERBB2CYP3A4ADORA3 | |
| SCHEMBL21083737 | 0.94 | AGTR1 (0.88) | ABCB11EGFRERBB2CYP3A4ADORA3 | |
| SCHEMBL20257353 | 0.93 | CYP3A4 (0.87) | ABCB11EGFRERBB2CYP3A4ADORA3 | |
| SCHEMBL13707307 | 0.92 | CYP3A4 (0.86) | ABCB11EGFRERBB2CYP3A4ADORA3 | |
| SCHEMBL2624570 | 0.92 | AGTR1 (0.85) | ABCB11EGFRERBB2CYP3A4ADORA3 | |
| SCHEMBL21084006 | 0.91 | AGTR1 (0.83) | ABCB11EGFRERBB2CYP3A4ADORA3 | |
| SCHEMBL21083993 | 0.90 | AGTR1 (0.80) | ABCB11EGFRERBB2CYP3A4ADORA3 | |
| SCHEMBL2624575 | 0.88 | AGTR1 (0.79) | ABCB11EGFRERBB2CYP3A4ADORA3 | |
| SCHEMBL21083591 | 0.88 | AGTR1 (0.78) | ABCB11EGFRERBB2CYP3A4ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12535 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260048013-A1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2026-02-19 | — | — | US | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4076652-B1 | A PHARMACEUTICALLY ACCEPTABLE SALT OF ATRASENTAN FOR USE IN A METHOD OF TREATING IGA NEPHROPATHY | CHINOOK THERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4638742-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2025-10-29 | — | — | EP | claimed |
| US-12409173-B2 | Repurposing FDA-approved drugs as a novel cancer therapeutic avenue through inhibition of PRMT5 | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-09-09 | — | — | US | claimed |
| CN-120142485-A | Detection method of impurity hydrazine hydrate in candesartan cilexetil intermediate | 珠海润都制药股份有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-1192697-A | Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for the treatment of congestive heart failure | SEARLE & CO (US) | 1998-09-09 | — | — | CN | claimed |
| WO-1998030216-A1 | USE OF ANGIOTENSIN II ANTAGONISTS TO TREAT SYMPTOMATIC HEART FAILURE | MERCK & CO., INC. (US) | 1998-07-16 | — | — | WO | claimed |
| EP-0835106-A1 | METHOD OF TREATING RENAL DISEASE USING AN ACE INHIBITOR AND AN AII ANTAGONIST | MERCK & CO. INC. (US) | 1998-04-15 | — | — | EP | claimed |
| EP-0831911-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0831910-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1997002032-A1 | METHOD OF TREATING RENAL DISEASE USING AN ACE INHIBITOR AND AN AII ANTAGONIST | MERCK & CO., INC. (US) | 1997-01-23 | — | — | WO | claimed |
| WO-1996040256-A1 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION OF AN ANGIOTENSIN II ANTAGONIST AND SPIRONOLACTONE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040258-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040257-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040255-A2 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION THERAPY OF AN ANGIOTENSIN II ANTAGONIST AND AN EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |